ICD-10 Codes of Esophageal Cancer: Complete Coding and Billing Guide
November 12, 2026
An omission of one fact on a report for an oncology condition may result in a different code for a medical claim. Esophageal cancer poses this problem due to the need to locate the exact site of the tumor, ascertaining the status of the tumor, and discerning whether the condition is active or is part of a patient’s history of cancer.
Codes used for the esophageal cancer condition belong to category C15, which is known as Malignant Neoplasm of Esophagus. The code selected by the coder is based mainly on the site identified. Codes include C15.5 for malignant neoplasm of the lower third of the esophagus and C15.9 for malignant neoplasm of the esophagus.
Esophageal Cancer ICD-10 Codes at a Glance
The ICD-10-CM classification organizes active primary esophageal malignancies by anatomical location. Category C15 contains five specific diagnosis codes for reporting these cancers.
| ICD-10-CM code | Description |
| C15.3 | Malignant neoplasm of upper third of esophagus |
| C15.4 | Malignant neoplasm of middle third of esophagus |
| C15.5 | Malignant neoplasm of lower third of esophagus |
| C15.8 | Malignant neoplasm of overlapping sites of esophagus |
| C15.9 | Malignant neoplasm of esophagus, unspecified |
| Z85.01 | Personal history of malignant neoplasm of esophagus |
Codes one through five are for active esophageal cancers. Z85.01 pertains to a past history of esophageal cancer if the scenario satisfies the personal history code criteria.
Note: C15 is the general heading; however, it is not a complete billable code. A code needs to be selected.
The FY 2027 ICD-10-CM update applies to dates of service from October 1, 2026 to September 30, 2027.
How Tumor Location Determines the Correct ICD-10 Code
A diagnosis of esophageal cancer alone does not offer enough information to code with the greatest specificity. The operative report, the results of pathology, the endoscopy results, and the diagnosis of the treating doctor will all contribute to determining the site of the tumor.
C15.3 — Upper Third of Esophagus
The code above is applied to primary malignancies of the esophagus upper third.
For example, the physician gives a diagnosis saying there is a primary malignant neoplasm of the esophagus upper third. And the coder encodes it by C15.3.
Proof of the malignancy and localization needs to be done in the medical record.
C15.4 — Middle Third of Esophagus
The code C15.4 is used to identify malignant tumors of the middle third of the esophagus.
Let us consider a scenario where a patient has gone for a diagnosis that reveals a malignant tumor in the middle third of the esophagus and then seeks an oncology examination. The physician specifies the exact site.
The coder can use C15.4 code for that particular diagnosis.
C15.5 — Lower Third of Esophagus
C15.5 is the ICD-10-CM code for malignant neoplasm of the lower third of the esophagus.
A frequent coding scenario entails a patient with known distal esophageal adenocarcinoma. In case the tumor is described by the treating provider as a primary cancer in the lower third, C15.5 is the right choice for coding.
Nevertheless, a coder has to be careful with the documentation pertaining to the gastroesophageal junction. A tumor located close to the stomach does not always imply esophageal carcinoma.
It is essential for the doctor to determine the primary anatomical location first.
C15.8 — Overlapping Sites of Esophagus
C15.8 is used to classify an overlapping malignant lesion that involves contiguous lesions of the esophagus where the site of origin is not known.
An example of this situation is when the physician records a continuous lesion of the malignant type located in the mid and lower portions of the esophagus, but does not specify the original site.
This may be the case for C15.8.
The coder should not use an overlapping site code because the report mentions two different tumor sites..
C15.9 — Malignant Neoplasm of Esophagus, Unspecified
C15.9 codes for esophageal malignancy when no documentation is available for the specific site.
Imagine a referral note that confirms esophageal cancer but does not confirm the exact site of the tumor as upper, middle, or lower one-third.
C15.9 can be used in such a situation appropriately.
However, whenever there is documentation about the precise site in other clinical documents, then the coder should look for proper documentation.
Esophageal Adenocarcinoma ICD-10 Code: Does Histology Change the Code?
Esophageal adenocarcinoma is considered to be a histological subtype of esophageal carcinoma. While the pathologic examination determines the specific cellular features of the tumor, C15 ICD-10-CM codes mainly reflect the anatomical site of the malignancy.
Thus, there is no unique ICD-10-CM code for esophageal adenocarcinoma.
Some examples are as follows:
- Lower third esophageal adenocarcinoma: C15.5
- Middle third esophageal adenocarcinoma: C15.4
- Esophageal adenocarcinoma with unspecified site: C15.9
The same concept applies to the diagnosis of esophageal squamous cell carcinoma.
Why the Gastroesophageal Junction Matters
Malignancies in the area of the gastroesophageal junction make a significant coding difference.
A clinician can describe malignancy of the lower esophagus, the cardia of the stomach, or the gastroesophageal junction. This may result in various anatomical coding categories.
C16.0 is the code for the malignant neoplasm of the cardia and has the gastroesophageal junction in its coding category.
Hence, one should not simply pick the C15.5 code whenever there is a malignancy in the vicinity of the gastroesophageal junction.
A query to the physician will help clear up conflicting documentation before billing.
ICD-10 Code for History of Esophageal Cancer
Previous history of cancer is not always an indication for reporting an active malignancy.
Z85.01 — Personal history of malignant neoplasm of esophagus describes individuals who had primary esophageal cancer before and qualify for personal history codes.
According to the FY 2027 ICD-10-CM Guidelines, coders should report the active primary malignancy even after the initial treatment when treatment is still targeted at the primary malignancy. When treatment has been completed and no evidence of malignancy exists at the primary site, a personal history code would be applicable.
Think about the following scenarios.
Scenario A: Treatment Ongoing
The patient is treated for esophagectomy and further treatment is administered to treat the primary cancer. The appropriate active malignancy code is reported based on the official guidelines.
Scenario B: Treatment Completed
The patient is done with the treatment for cancer, has no evidence of any primary cancer, and visits the clinic for surveillance. Personal history code Z85.01 is applicable; Z08 can be the primary code in case of the follow-up examination after completion of treatment.
This helps avoid confusion for billing departments by assuming that the patient is actively suffering from cancer just because his or her problem list states so.
How Esophageal Cancer ICD-10 Codes Affect Medical Billing
Once claims can include consultations for diagnosis, surgical procedures, radiation treatment, chemotherapy, and follow-ups. Each visit must be coded based on the purpose of the visit.
1. Cancer Diagnosis and Treatment Encounters
If the encounter is for treatment of a primary malignancy of the esophagus, the C15 code associated with that encounter would usually be the cause of the service.
But whether the code appears at all and where it appears will depend on the encounter.
2. Chemotherapy, Immunotherapy, and Radiation Therapy
The official guidelines establish specific sequencing requirements for encounters chiefly involving administration of antineoplastic treatment.
| Encounter purpose | First-listed diagnosis under applicable guidelines |
| Antineoplastic chemotherapy | Z51.11 |
| Antineoplastic immunotherapy | Z51.12 |
| Antineoplastic radiation therapy | Z51.0 |
| Treatment directed at the primary malignancy | Appropriate primary malignancy code, unless an exception applies |
When the encounter chiefly involves the specified antineoplastic therapy, coders generally report the underlying malignancy as an additional diagnosis.
Special circumstances, including brachytherapy and encounters involving multiple treatments, require closer guideline review.
Centers for Medicare & Medicaid Services
3. Metastatic Esophageal Cancer
In cases where the esophageal cancer metastasizes to another body part, billing staff need to be able to identify whether the original malignancy is the main one or if a secondary malignancy exists.
Consider the case of an individual having an esophageal cancer with a confirmed case of metastasis in the liver.
Depending on the circumstances surrounding the encounter, the biller can decide to use the codes for both primary esophageal cancer and secondary malignancy.
4. Diagnostic Procedures and Medical Necessity
ICD-10-CM codes capture diagnoses and the reason for the encounter. The CPT and HCPCS codes cover the process performed by the physician.
In case one has a claim for endoscopy, biopsy, imaging, or oncology services on the same malignant condition, he will need different procedure codes.
This means that billing departments need to ensure that the service rendered, the diagnosis, and other documentation is accurate regardless of the malignancy.
Common Esophageal Cancer Coding Errors That Delay Claims
Even experienced oncology billing teams encounter documentation gaps. The following errors deserve attention before submission.
| Common coding problem | Practical correction |
| Selecting C15.9 despite documented tumor location | Review the current physician assessment and supporting records |
| Coding distal esophageal and gastric cardia tumors interchangeably | Confirm the primary anatomical site |
| Reporting active cancer after completed treatment without evidence of disease | Evaluate the requirements for Z85.01 |
| Using Z85.01 while treatment remains directed at the primary site | Review active malignancy coding guidelines |
| Missing a documented secondary malignancy | Assign the appropriate additional diagnosis when applicable |
| Incorrect diagnosis sequencing during therapy | Review encounter purpose and applicable Z51 rules |
One of the most preventable errors relates to inconsistent documentation. For instance, the pathology report may mention that the tumor is located in distal esophagus while the referring note may use another anatomical location. It would be appropriate for coders to identify inconsistent information and ask clarification from the treating physician.
A Practical Pre-Submission Checklist for Oncology Billing Teams
Go over the following points prior to filing an oncology claim in order to prevent coding mistakes and unnecessary denials.
– Make sure you have the correct cancer diagnosis noted in documentation.
– Ensure that the anatomical location of the tumor is documented correctly.
– Distinguish active cancer from cancer history.
– Go through the pathology and medical records.
– Determine the primary site and any metastasis.
– Ensure that the ICD-10-CM codes and sequencing of diagnoses is accurate.
– Ensure that the CPT codes match the service provided.
– Check payer coverage and authorization.
A consistent review process helps billing teams identify coding and documentation issues before they trigger payer questions, rejections, or denials.
Strengthening Esophageal Cancer Coding Across the Revenue Cycle
Accurate oncology billing entails more than just selecting the proper diagnosis code.
The physicians need to mention the location of the primary tumor, the present disease condition, the course of the treatment, and any confirmed cases of secondary malignancies. The medical coders need to code the above information without adding any assumptions about the clinical situation.
The billing managers need to follow up on the coding changes and how the payers have reacted. In case of multiple requests for documentation, the revenue cycle team needs to assess the workflow rather than handle every claim individually.
The coordination between oncologists, coders, and billing team members helps in having a consistent diagnosis reporting process.
Conclusion
Esophageal cancer ICD-10 coding begins with asking these three questions: where is the malignancy located? Is the patient still actively being treated for their cancer? Which service led to the encounter?
Active primary esophageal cancers are coded with C15.3-C15.9 based on where they are located, whereas Z85.01 indicates a qualifying personal history of cancer.
By consistently ensuring these differences are determined, providers and billing teams will increase documentation accuracy and reduce unnecessary coding errors.
Frequently Asked Questions
What is the ICD-10 code for esophageal cancer?
Malignant neoplasm of the esophagus falls under ICD-10-CM category C15. The individual code used for the condition is between C15.3 and C15.9, according to the specific location.
What does ICD-10 code C15.9 mean?
C15.9 is used for malignant neoplasm of esophagus, unspecified. It is coded where there is evidence of esophageal malignancy but the site within the esophagus cannot be determined.
What is the ICD-10 code for lower-third esophageal cancer?
C15.5 codes for malignant neoplasm in the lower third of the esophagus. The medical record should reflect this particular anatomic site.
What is the ICD-10 code for a history of esophageal cancer?
The code Z85.01 describes personal history of malignant neoplasm of esophagus when the primary cancer is no longer present at the site and where no further therapy is directed at the malignant lesion.
Does esophageal adenocarcinoma have a separate ICD-10 code?
Not all codes within the ICD-10-CM system apply to all cases of esophageal adenocarcinoma. The coders use C15 code based on the documented location of the tumor.
Can billing teams use C15.9 on insurance claims?
Yes, but it is a full diagnosis code. Yet, it is best to use a more precise code when the location of the tumor has been established.
Does metastatic esophageal cancer require additional diagnosis codes?
It can be done. Secondary malignant neoplasms must be coded appropriately if they are present, while the order of coding is determined by the nature of the encounter.